Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Marco Basset

Showing results (11-20 of 51) with videos related to

Pageof 6
Sort By:
Blood Cancer Journal|September 3, 2020
Indicators of profound hematologic response in AL amyloidosis: complete response remains the goal of therapyPaolo Milani, Marco Basset, Mario Nuvolone, et al.
Amyloid : the International Journal of Experimental and Clinical Investigation : the Official Journal of the International Society of Amyloidosis|April 25, 2017
Urinary albumin to creatinine ratio in diagnosis and risk stratification of renal AL amyloidosisGiovanni Palladini, Paolo Milani, Marco Basset, et al.
Blood|June 30, 2022
Early cardiac response is possible in stage IIIb cardiac AL amyloidosis and is associated with prolonged survivalMarco Basset, Paolo Milani, Andrea Foli, et al.
Biomedicines|May 16, 2023
A Strategy for the Selection of RT-qPCR Reference Genes Based on Publicly Available Transcriptomic DatasetsAlice Nevone, Francesca Lattarulo, Monica Russo, et al.
Blood|May 20, 2015
A European collaborative study of cyclophosphamide, bortezomib, and dexamethasone in upfront treatment of systemic AL amyloidosisGiovanni Palladini, Sajitha Sachchithanantham, Paolo Milani, et al.
Blood Advances|April 7, 2020
Daratumumab in light chain deposition disease: rapid and profound hematologic response preserves kidney functionPaolo Milani, Marco Basset, Paola Curci, et al.
Amyloid : the International Journal of Experimental and Clinical Investigation : the Official Journal of the International Society of Amyloidosis|April 25, 2017
Severity and reversibility of cardiac dysfunction and residual concentration of amyloidogenic light chain predict overall survival of patients with AL amyloidosis who attain complete responseGiovanni Palladini, Paolo Milani, Marco Basset, et al.
Amyloid : the International Journal of Experimental and Clinical Investigation : the Official Journal of the International Society of Amyloidosis|October 20, 2024
AA amyloidosis in vertebrates: epidemiology, pathology and molecular aspectsValentina Moccia, Claudia Maria Tucciarone, Silvia Garutti, et al.
Blood|August 16, 2018
Treatment of AL amyloidosis with bendamustine: a study of 122 patientsPaolo Milani, Stefan Schönland, Giampaolo Merlini, et al.
European Journal of Radiology|June 27, 2020
CT features in amyloidosis of the respiratory system - Comprehensive analysis in a tertiary referral center cohortSimone Christine Brandelik, Claus Peter Heussel, Hans-Ulrich Kauczor, et al.
Pageof 6

Showing results (11-20 of 51) with videos related to

Sort By:
Pageof 6
Blood Cancer Journal|September 3, 2020
Indicators of profound hematologic response in AL amyloidosis: complete response remains the goal of therapyPaolo Milani, Marco Basset, Mario Nuvolone, et al.
Amyloid : the International Journal of Experimental and Clinical Investigation : the Official Journal of the International Society of Amyloidosis|April 25, 2017
Urinary albumin to creatinine ratio in diagnosis and risk stratification of renal AL amyloidosisGiovanni Palladini, Paolo Milani, Marco Basset, et al.
Blood|June 30, 2022
Early cardiac response is possible in stage IIIb cardiac AL amyloidosis and is associated with prolonged survivalMarco Basset, Paolo Milani, Andrea Foli, et al.
Biomedicines|May 16, 2023
A Strategy for the Selection of RT-qPCR Reference Genes Based on Publicly Available Transcriptomic DatasetsAlice Nevone, Francesca Lattarulo, Monica Russo, et al.
Blood|May 20, 2015
A European collaborative study of cyclophosphamide, bortezomib, and dexamethasone in upfront treatment of systemic AL amyloidosisGiovanni Palladini, Sajitha Sachchithanantham, Paolo Milani, et al.
Blood Advances|April 7, 2020
Daratumumab in light chain deposition disease: rapid and profound hematologic response preserves kidney functionPaolo Milani, Marco Basset, Paola Curci, et al.
Amyloid : the International Journal of Experimental and Clinical Investigation : the Official Journal of the International Society of Amyloidosis|April 25, 2017
Severity and reversibility of cardiac dysfunction and residual concentration of amyloidogenic light chain predict overall survival of patients with AL amyloidosis who attain complete responseGiovanni Palladini, Paolo Milani, Marco Basset, et al.
Amyloid : the International Journal of Experimental and Clinical Investigation : the Official Journal of the International Society of Amyloidosis|October 20, 2024
AA amyloidosis in vertebrates: epidemiology, pathology and molecular aspectsValentina Moccia, Claudia Maria Tucciarone, Silvia Garutti, et al.
Blood|August 16, 2018
Treatment of AL amyloidosis with bendamustine: a study of 122 patientsPaolo Milani, Stefan Schönland, Giampaolo Merlini, et al.
European Journal of Radiology|June 27, 2020
CT features in amyloidosis of the respiratory system - Comprehensive analysis in a tertiary referral center cohortSimone Christine Brandelik, Claus Peter Heussel, Hans-Ulrich Kauczor, et al.
Pageof 6